Press-release for stocks

treatment crawled time : 15:00

save search

Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | News | $30.8 2.87% -1.14% 1.2M

Health Technology

| 2.53% | O: -0.4% H: 3.01% C: 2.94%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| 2.04% | O: 0.83% H: 1.35% C: 1.2%
ABT | News | $107.28 1.91% 0.18% 10M

Health Technology

| 0.83% | O: -0.39% H: 1.69% C: 1.23%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| 1.74% | O: 0.83% H: 1.83% C: 0.89%
first treatment for

Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
Published: 2024-04-16 (Crawled : 15:00) - biospace.com/
PPCB | $0.001 -41.86% 11M

Manufacturing

| -7.14% | O: 0.0% H: 14.29% C: -7.14%
patent cancer biopharma for grant

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-03-28 (Crawled : 15:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K

Manufacturing

| -13.16% | O: 0.82% H: 0.0% C: -2.54%
keytruda license bladder cancer treatment medical application advanced

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.
Published: 2024-03-25 (Crawled : 15:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| -2.86% | O: -100.0% H: NaN% C: Infinity%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -1.94% | O: -0.08% H: 0.15% C: -0.44%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| -5.75% | O: 0.06% H: 0.96% C: 0.26%
CAH | $108.19 2.07% 0.0% 1.5M

Distribution Services

| -2.54% | O: 0.02% H: 0.73% C: -0.02%
LNTH | $63.8 2.36% 2.3% 800K

Health Technology

| 8.12% | O: 0.1% H: 1.98% C: -0.08%
reach cancer treatment market

Regeneron Hit With Two CRLs, J&J’s PAH Treatment Approved
Published: 2024-03-25 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
PRGO | News | $30.8 2.87% -1.14% 1.2M

Health Technology

| -1.66% | O: 0.35% H: 0.35% C: -1.34%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -4.92% | O: 0.04% H: 0.0% C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M

Health Technology

| -2.98% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.68% | O: 0.42% H: 0.0% C: 0.0%
approved treatment

Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
Published: 2024-03-08 (Crawled : 15:00) - biospace.com/
SENS | $0.3992 -4.04% 0.45% 2M

Electronic Technology

| -32.33% | O: 1.51% H: 6.65% C: 4.18%
eversense conference approval international advanced diabetes study

MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
Published: 2024-03-05 (Crawled : 15:00) - biospace.com/
MAIA | $2.15 9.69% 0.0% 100K

| 48.28% | O: -3.45% H: 10.71% C: 5.71%
ceo cancer pipeline treatment

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
Published: 2024-03-04 (Crawled : 15:00) - biospace.com/
ICCM | $1.23 -4.03% 120K

Manufacturing

| Email alert Add to watchlist
prosense treatment alternative study

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| 0.45% | O: 0.23% H: 0.44% C: 0.14%
drug review food tumors treatment application advanced

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
Published: 2024-02-13 (Crawled : 15:00) - biospace.com/
EWTX | $15.23 -1.42% -1.44% 540K

Manufacturing

| -19.63% | O: -2.9% H: 2.99% C: 2.77%
edg-5506 fda treatment designation duchenne

FDA Decisions: Agency Greenlights Takeda's Oral EoE Treatment in Company's Second Straight Win
Published: 2024-02-12 (Crawled : 15:00) - biospace.com/
PRGO | News | $30.8 2.87% -1.14% 1.2M

Health Technology

| -3.39% | O: 0.31% H: 1.44% C: 1.31%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -5.16% | O: 0.41% H: 0.0% C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M

Health Technology

| -4.43% | O: -0.64% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -0.64% | O: -0.86% H: 0.0% C: 0.0%
fda treatment

Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
Published: 2024-01-29 (Crawled : 15:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.68% | O: 0.12% H: 0.0% C: 0.0%
il-10 treatment collaboration sanofi

Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K

Health Technology

| -7.01% | O: -0.25% H: 1.25% C: 0.99%
pharmaceuticals meeting

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -0.41% | O: -0.35% H: 0.0% C: 0.0%
TEVA | $12.86 0.63% 0.0% 10M

Health Technology

| 32.71% | O: -0.52% H: 3.73% C: 1.87%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -0.64% | O: -1.09% H: 0.0% C: 0.0%
disease treatment collaboration teva deal

LHC Group Gets Center-Stage Treatment At UnitedHealth Group’s Investor Day
Published: 2023-11-30 (Crawled : 15:00) - lhcgroup.com
LHCG | News | $169.81 0.47% -0.03% 0

Health Services

| Email alert Add to watchlist
day group treatment

FDA Decisions: First Treatment for Desmoid Tumors and a Dry Eye Rejection for Aldeyra
Published: 2023-11-28 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -2.28% | O: -1.89% H: 0.02% C: 0.02%
PRGO | News | $30.8 2.87% -1.14% 1.2M

Health Technology

| 0.16% | O: 0.78% H: 0.81% C: -1.71%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -2.23% | O: 0.09% H: 0.0% C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M

Health Technology

| 4.45% | O: -0.24% H: 0.03% C: -0.39%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -2.83% | O: -1.41% H: 0.87% C: 0.0%
fda tumors treatment eye

Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
Published: 2023-11-02 (Crawled : 15:00) - biospace.com/
LEGN | $46.14 -2.08% -2.12% 1.2M

Health Technology

| -30.86% | O: 0.52% H: 0.28% C: -3.54%
biotech treatment meeting

A Differentiated DMD Treatment and Two New Ulcerative Colitis Therapies
Published: 2023-10-27 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology